SCHEMBL10249296

SCHEMBL10249296

Cc1c(C(Nc2ccc(C(=O)N(C)CCC(=O)O)cc2)C2CCCCC2)oc2ccc(OCc3ccnc(F)c3)cc12

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
FFAR1 O14842 2/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
RCE1 Q9Y256 1/20 0.32
TP53 P04637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
KMT2A Q03164 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719699 0.94 KDM4E (0.34) NPC1RAB9ATDP1KMT2AKDM4E
SCHEMBL721186 0.92 NPC1 (0.35) CYP4F2CYP4A11NPC1RAB9ATP53
SCHEMBL716904 0.91 MEN1 (0.35) KMT2A
SCHEMBL720498 0.90 CASP3 (0.40) CYP4F2CYP4A11NPC1RAB9ALMNA
SCHEMBL718989 0.89 GCG (0.41) NPC1RAB9A
SCHEMBL719031 0.88 GPR132 (0.40) CYP4F2CYP4A11NPC1RAB9ALMNA
SCHEMBL721587 0.88 KDM4E (0.35) CYP4F2CYP4A11NPC1RAB9ALMNA
SCHEMBL717011 0.87 GCG (0.35) CYP4F2CYP4A11NPC1RAB9ALMNA
SCHEMBL3402539 0.86 CASP3 (0.38) CYP4F2CYP4A11NPC1RAB9ALMNA
SCHEMBL3400948 0.86 ALOX5 (0.39) CYP4F2CYP4A11NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP CYP4F2 471/4885CYP4A11 58/4885NPC1 902/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP CYP4F2 471/4885CYP4A11 58/4885NPC1 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.